Effect of Metformin duration and Glibenclamide co-Administration on incidence of stroke in type 2 diabetic patients

Aim: :Stroke is one of the most destructive neurological events. Diabetes mellitus confirmed as independent risk factor. The study aimed to correlate the effect of duration and combination of oral hypoglycemic agents (metformin and glibenclamide) to the incidence of ischemic stroke in type 2 diabeticpatients. Methods: A cross-sectional study was carried out on type 2 diabetic patients with or without history of ischemic stroke. Patients were divided into: Group I(metformin)and Group II (metformin and glibenclamide). Laboratory analysis involved metabolic and oxidative parameters. Results: Good glycemic control (HbA1c<7) was predominant in Group I, poor and very poor glycemic control (HbA1c>7) were predominant in Group II. Group I revealed significant decrease in the MDA level and TG/HDL ratio (P<0.05). While Group II showed significant increase in HbA1c, TG/HDL ratio, PN, and other metabolic parameters (TC, TG and HDL)(P<0.05) with decrease in MDA after 5 years duration (P<0.01). Treatment (<5 years), FBS, HbA1c and TC showed significant correlation with ischemic stroke (p<0.01). While treatment (>5 years), FBS, HbA1c as well as MDA showed a significant correlation with ischemic stroke (p<0.05). Conclusion: Metformin monotherapy significantly diminishes oxidative stress and restores antioxidant capacity,suggesting better efficacy compared with co-administration with glibenclamide.